Yong Yuan - Bristol Myers Squibb, Princeton, NJ, USA. Electronic address: yong.yuan@bms.com.

基本信息

浏览量：3

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 129 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

David P. Carbone, Tudor-Eliade Ciuleanu,Michael Schenker,Manuel Cobo, Stephanie Bordenave,Oscar Juan-Vidal,Juliana Menezes,Niels Reinmuth,Eduardo Richardet, Ying Cheng,Hideaki Mizutani,Enriqueta Felip,

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2024）

引用0浏览0WOS引用

Abstract 3817: Real-world clinical outcomes in patients with advanced ROS1+non-small cell lung cancer in the US

Reginald Villacorta, Saurabh Ray,Yong Yuan, Sushupta Vijapur, Sonia Kim, Haiyan Sun, Sky Myers,Vincent Lam

Cancer Researchno. 6_Supplement (2024): 3817-3817

引用0浏览0引用

Abstract 3819: Real-world long-term survival outcomes of first-line immunotherapy-based regimens in advanced non-small cell lung cancer

David Waterhouse, Saurabh Ray, Keith A. Betts, Sophie Gao,Yong Yuan, Manasvi Sundar, Shumin Rui,David Stenehjem

Cancer Researchno. 6_Supplement (2024): 3819-3819

引用0浏览0引用

Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Alexander Drilon,D Ross Camidge,Jessica J Lin,Sang-We Kim,Benjamin J Solomon,Rafal Dziadziuszko,Benjamin Besse,Koichi Goto,Adrianus Johannes de Langen,Jürgen Wolf,Ki Hyeong Lee,Sanjay Popat,

The New England journal of medicineno. 2 (2024): 118-131

引用0浏览0WOS引用

Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis

Kenneth O'Byrne,Evan Popoff,Firas Badin,Adam Lee,Yong Yuan,Greta Lozano-Ortega,Laura J Eccles,Nebibe Varol,Nathalie Waser,John R Penrod, Sarah Goring

Lung Cancer（2023）

引用3浏览0WOS引用

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

Martin Reck,Tudor-Eliade Ciuleanu,Manuel Cobo,Michael Schenker,Bogdan Zurawski,Juliana Menezes,Eduardo Richardet,Jaafar Bennouna,Enriqueta Felip,Oscar Juan-Vidal,Aurelia Alexandru,Ying Cheng,

Eur J Cancer（2023）

引用3浏览0WOS引用

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

Zhimin Zeng,Xiaoying Qian,Fanrong Liu,Yong Wang,Yong Yuan,Fang Chen,Xinwei Zhang,Shangkun Yuan,Renfang Chen,Bo Yu,Tong Wang, Yulong Yin,

Frontiers in Immunology (2023)

引用1浏览0引用

Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data

Julie E Park,Harlan Campbell, Kevin Towle,Yong Yuan, Jeroen P Jansen,David Phillippo,Shannon Cope

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Researchno. 3 (2023): 278-286

引用0浏览0WOS引用

Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey

Hollie Bailey,Adam Lee,Laura Eccles,Yong Yuan, Helen Burlison,Cameron Forshaw,Nebibe Varol

BMC cancer（2023）

引用1浏览0WOS引用

EP11.03-23 Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis

K. O'Byrne, E. Popoff, F. Badin,A. Lee,Y. Yuan, S. Goring, L.J. Eccles, N. Varol, N. Waser,J.R. Penrod, G. Lozano-Ortega

Journal of Thoracic Oncologyno. 11 (2023): S629-S630

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn